Category: Latest Studies

Translational Pharmacology, In Vitro Thresholds & Evidence Hierarchies

Evaluating scientific literature requires distinguishing between in vitro cell-culture experiments and in vivo clinical trial results. Preclinical in vitro assays often demonstrate broad biological activities—including inhibition of nuclear import receptors (importin α/β1) and multi-drug resistance reversal—at micromolar drug concentrations.

However, achieving micromolar concentrations in vivo requires administering dosages 50 to 100 times higher than the maximum tolerated human and canine doses. In clinical pharmacokinetic studies, safe standard dosing yields peak plasma concentrations in the low nanomolar range (typically 20 to 50 ng/mL), establishing an insurmountable translational gap between petri-dish findings and physiological efficacy.

Evidence-based veterinary medicine prioritizes double-blind, randomized controlled clinical trials (RCTs) and systematic Cochrane reviews over anecdotal reports. Large-scale clinical evaluations consistently reinforce ivermectin’s status as a gold-standard anthelmintic and ectoparasiticide while refuting unverified off-label antiviral claims at physiological concentrations.